Sweden · Delayed Price · Currency is SEK Biovica International AB Statistics
Total Valuation
STO:BIOVIC.B has a market cap or net worth of SEK 143.04 million. The enterprise value is 76.92 million.
| Market Cap | 143.04M |
| Enterprise Value | 76.92M |
Important Dates
The next confirmed earnings date is Thursday, September 10, 2026.
| Earnings Date | Sep 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:BIOVIC.B has 291.91 million shares outstanding. The number of shares has increased by 153.64% in one year.
| Current Share Class | 277.49M |
| Shares Outstanding | 291.91M |
| Shares Change (YoY) | +153.64% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 14.68% |
| Owned by Institutions (%) | 17.31% |
| Float | 244.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.61 |
| PB Ratio | 1.66 |
| P/TBV Ratio | 1.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.30, with a Debt / Equity ratio of 0.05.
| Current Ratio | 4.30 |
| Quick Ratio | 4.06 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.07 |
| Interest Coverage | -177.07 |
Financial Efficiency
Return on equity (ROE) is -107.86% and return on invested capital (ROIC) is -63.76%.
| Return on Equity (ROE) | -107.86% |
| Return on Assets (ROA) | -51.13% |
| Return on Invested Capital (ROIC) | -63.76% |
| Return on Capital Employed (ROCE) | -78.74% |
| Weighted Average Cost of Capital (WACC) | 10.27% |
| Revenue Per Employee | 539,400 |
| Profits Per Employee | -2.79M |
| Employee Count | 25 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 0.02 |
Taxes
In the past 12 months, STO:BIOVIC.B has paid 352,000 in taxes.
| Income Tax | 352,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.38% in the last 52 weeks. The beta is 1.11, so STO:BIOVIC.B's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | -24.38% |
| 50-Day Moving Average | 0.37 |
| 200-Day Moving Average | 0.42 |
| Relative Strength Index (RSI) | 69.94 |
| Average Volume (20 Days) | 672,621 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, STO:BIOVIC.B had revenue of SEK 13.49 million and -69.86 million in losses. Loss per share was -0.30.
| Revenue | 13.49M |
| Gross Profit | 13.44M |
| Operating Income | -70.64M |
| Pretax Income | -69.51M |
| Net Income | -69.86M |
| EBITDA | -61.82M |
| EBIT | -70.12M |
| Loss Per Share | -0.30 |
Balance Sheet
The company has 70.41 million in cash and 4.30 million in debt, with a net cash position of 66.11 million or 0.23 per share.
| Cash & Cash Equivalents | 70.41M |
| Total Debt | 4.30M |
| Net Cash | 66.11M |
| Net Cash Per Share | 0.23 |
| Equity (Book Value) | 86.33M |
| Book Value Per Share | 0.30 |
| Working Capital | 61.64M |
Cash Flow
In the last 12 months, operating cash flow was -62.81 million and capital expenditures -474,000, giving a free cash flow of -63.28 million.
| Operating Cash Flow | -62.81M |
| Capital Expenditures | -474,000 |
| Depreciation & Amortization | 1.09M |
| Net Borrowing | -3.00M |
| Free Cash Flow | -63.28M |
| FCF Per Share | -0.22 |
Margins
| Gross Margin | 99.68% |
| Operating Margin | -523.85% |
| Pretax Margin | -515.45% |
| Profit Margin | n/a |
| EBITDA Margin | -409.48% |
| EBIT Margin | -464.43% |
| FCF Margin | n/a |
Dividends & Yields
STO:BIOVIC.B does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -153.64% |
| Shareholder Yield | -153.64% |
| Earnings Yield | -48.84% |
| FCF Yield | -44.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
STO:BIOVIC.B has an Altman Z-Score of -5.93 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.93 |
| Piotroski F-Score | 4 |